The Zhitong Finance App learned that LLY.US (LLY.US) has agreed to acquire the privately held Calytrix Bio Inc., with a transaction value of up to 1.5 billion US dollars. This is Lilly's latest move to continue to acquire and lay out the cancer and autoimmune disease racetrack.
A statement issued by Eli Lilly on Monday said that the deal included an undisclosed amount of cash down payment along with milestone payments. The payment terms depended on whether specific clinical goals could be achieved.
After the news was announced, Eli Lilly's US stock rose about 0.6% in the premarket.
According to information, Lilly is famous for its popular weight loss drug Zepbound, and the world's leading pharmaceutical company is continuing major mergers and acquisitions, continuously developing new tracks and consolidating technical capabilities in key areas, hoping to open up a new growth curve outside of the diabetes and obesity business.
Calytrix is an R&D company that focuses on antibody therapies for rare hematomas. This acquisition also continues Eli Lilly's plan to acquire Ajax Therapeutics on the same track earlier this year.
Calytrix Bio was founded by the J.P. Morgan Life Sciences private equity team in 2025. The start-up capital came from J.P. Morgan's venture capital division and Westlake BioPartners, and Avoro Ventures also participated in subsequent funding. The original purpose of the company was to overcome a type of rare hematologic tumor originating in the bone marrow.
The biotechnology company's core pipeline is an artificially synthesized target protein designed to target the genetic mutations that drive two chronic blood diseases: primary thrombocytosis and myelofibrosis. Currently, current treatments for these two diseases can only control symptoms and complications.